Cargando…
Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far
TNF-α inhibitor (TNFi) therapies have transformed the treatment of several rheumatic musculoskeletal diseases. However, the majority of TNFi’s are immunogenic and consequent anti-drug antibodies formation can impact on both treatment efficacy and safety. Several controversies exist in the area of im...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199532/ https://www.ncbi.nlm.nih.gov/pubmed/29325166 http://dx.doi.org/10.1093/rheumatology/kex434 |